Interleukin-18 promoter polymorphism and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients

Kidney and Blood Pressure Research

Volumn 35, Issue 1, 2012, Pages 1-8

  Grzegorzewska, Alicja E ^a   Wobszal, Piotr ^a   Jagodziński, Paweł P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Antibodies to surface antigen of hepatitis B virus; Hemodialysis; Interleukin 18 gene

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 18;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOTYPE; HEMODIALYSIS; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VACCINATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; FEMALE; GENOTYPE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RENAL DIALYSIS; YOUNG ADULT;

EID: 81155159019     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000329932     Document Type: Article

References (42)

1. Oesterreicher C, Hammer J, Koch U, Pfeffel F, Sunder-Plassmann G, Petermann D, Müller C: HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. Kidney Int 1995; 48: 1967-1971.
2. Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, Gutkin A, Bernstein K, Giulivi A, Osiowy C: Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology 2004; 40: 1072-1077.
3. Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, Villa M, Barbisoni F, Rusconi E, Martin P: Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 2005; 21: 1341-1347.
4. Grzegorzewska AE, Kurzawska-Firlej D, Ratajewski W, Frankiewicz D, Niepolski L, Kaczmarek A: Antibodies to core antigen of hepatitis B virus in patients on renal replacement therapy: association with demographic, clinical and laboratory data. Nephron Clin Pract 2010; 114:c194-c203.
5. Lai KN, Tam JS, Lai FM, Lin HJ: Isolated presence of antibody to hepatitis B core antigen in dialysis patients: occurrence of sub clinical hepatitis? Am J Kidney Dis 1989; 13: 370-376.
6. Miller ER, Alter MJ, Tokars JI: Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999; 33: 356-360.
7. European Best Practice Guidelines. Prevention and management of HBV, HCV and HIV in HD patients. Nephrol Dial Transplant 2002; 17: 78-87.
8. Bruguera M, Cremades M, Mayor A, Sánchez Tapias JM, Rodés J: Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients. Postgrad Med J 1987; 63 (suppl 2):155-158.
9. Mitwalli A: Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 1996; 73: 417-420.
10. Sorkhi H, Roushan MR, Al Hashemi GH, Dooki MR, Bai S: Response to hepatitis B virus vaccination in haemodialysis patients with and without hepatitis C infection. East Mediterr Health J 2008; 14: 798-803.
11. Cendoroglo Neto M, Draibe SA, Silva AE, Ferraz ML, Granato C, Pereira CA, Sesso RC, Gaspar AM, Ajzen H: Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995; 10: 240-246.
12. Grzegorzewska AE, Kaczmarek-Leki V, M?ot-Michalska M, Niepolski L: Seroconversion rate to positivity for antibodies against core antigen of hepatitis B virus and duration of renal replacement therapy. Nephrol Dial Transplant 2011;26:970-976.
13. Scheerlinck JY: Genetic adjuvants for DNA vaccines. Vaccine 2001; 19: 2647-2656.
14. Yen H, Scheerlinck JY: Co-delivery of plasmid-encoded cytokines modulates the immune response to a DNA vaccine delivered by in vivo electroporation. Vaccine 2007; 25: 2575-2582.
15. Gracie JA, Robertson SE, McInnes IB: Interleukin-18. J Leukoc Biol 2003; 73: 213-224.
16. McInnes IB, Gracie JA, Leung BP, Wei XQ, Liew FY: Interleukin 18: a pleiotropic participant in chronic inflammation. Immunol Today 2000; 21: 312-315.
17. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K: Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998; 70: 281-312.
18. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H: Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19: 423-474.
19. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H: Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001; 12: 53-72.
20. Szkaradkiewicz A, Jopek A, Wysocki J: Effects of IL-12 and IL-18 on HBcAg-specific cytokine production by CD4 T lymphocytes of children with chronic hepatitis B infection. Antiviral Res 2005; 66: 23-27.
21. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S, Nakanishi K: IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998; 161: 3400-3407.
22. Tominaga K, Yoshimoto T, Torigoe K, Kurimoto M, Matsui K, Hada T, Okamura H, Nakanishi K: IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells. Int Immunol 2000; 12: 151-160.
23. Kim JJ, Nottingham LK, Tsai A, Lee DJ, Maguire HC, Oh J, Dentchev T, Manson KH, Wyand MS, Agadjanyan MG, Ugen KE, Weiner DB: Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants. J Med Primatol 1999; 28: 214-223.
24. Sánchez E, Palomino-Morales RJ, Ortego-Centeno N, Jiménez-Alonso J, González-Gay MA, López-Nevot MA, Sánchez-Román J, de Ramón E, González-Escribano MF, Pons-Estel BA, D'Alfonso S, Sebastiani GD, Italian collaborative group, Alarcón-Riquelme ME, Martín J: Identification of a new putative functional IL18 gene variant through an association study in systemic lupus erythematosus. Hum Mol Genet 2009; 18: 3739-3748.
25. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50 (RR-5):1-43.
26. Tsouchnikas I, Dounousi E, Xanthopoulou K, Papakonstantinou S, Thomoglou V, Tsakiris D: Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 2007; 68: 228-234.
27. Barakiewicz G, Juszczyk J, Grzegorzewska A, Czarnecki R: The results of the vaccination against hepatitis B ('Engerix B') in dialysed uraemic patients (in Polish). Hepatologia Pol 1996; 3: 11-14.
28. Zała̧czniki do rozporza̧dzenia Ministra Zdrowia z dnia 18 kwietnia 2005 r. Warsaw, Polish Ministry of Health, 2005.
29. Watanabe H, Matsushita S, Kamikawaji N, Hirayama K, Okumura M, Sasazuki T: Immune suppression gene on HLA-Bw54-DR4-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cells. Hum Immunol 1988; 22: 9-17.
30. Hatae K, Kimura A, Okubo R, Watanabe H, Erlich HA, Ueda K, Nishimura Y, Sasazuki T: Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype. Eur J Immunol 1992; 22: 1899-1905.
31. Walker M, Szumuness W, Stevens C, Rubinstein P: Genetics of anti-HBs responsiveness. I. HLA-DR7 and non-responsiveness to hepatitis vaccination. Transfusion 1981; 21: 601.
32. Petrescu L, Stancu S, Tardei G, Santimbrean C, Penescu M, Mircescu G: Tuberculin skin test, interferon-gamma assay, and T cells subpopulations in hemodialysis patients. J Ren Nutr 2010; 20(suppl 5):S109-S117.
33. Tang LL, Liu KZ: Recent advances in DNA vaccine of hepatitis virus. Hepatobiliary Pancreat Dis Int 2002; 1: 228-231.
34. Channarong S, Mitrevej A, Sinchaipanid N, Usuwantim K, Kulkeaw K, Chaicumpa W: Cloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine. Asian Pac J Allergy Immunol 2007; 25: 233-242.
35. Chen JZ, Zhu HH, Liu KZ, Chen Z: Enhancing cellular immune response to HBV M DNA vaccine in mice by codelivery of interleukin-18 recombinant. J Zhejiang Univ Sci 2004; 5: 467-471.
36. Palomino-Morales RJ, Vazquez-Rodriguez TR, Torres O, Morado IC, Castaneda S, Miranda-Filloy JA, Callejas-Rubio JL, Fernandez-Gutierrez B, Gonzalez-Gay MA, Martin J: Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis. Arthritis Res Ther 2010; 12:R51.
37. Cheng J, Imanishi H, Morisaki H, Liu W, Nakamura H, Morisaki T, Hada T: Recombinant HBsAg inhibits LPS-induced COX-2 expression and IL-18 production by interfering with the NFkB pathway in a human monocytic cell line, THP-1. J Hepatol 2005; 43: 465-471.
38. Fabrizi F, Dixit V, Martin P, Messa P: Metaanalysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharmacol Ther 2011; 33: 815-821.
39. Shatat HZ, Kotkat AM, Farghaly AG: Immune response to hepatitis B vaccine in haemodialysis patients. J Egypt Public Health Assoc 2000; 75: 257-275.
40. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, Kiaii M, Taylor PA, Levin A: Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003; 42: 1184-1192.
41. Izakovicova Holla L, Hrdlicková B, Schüller M, Buckova D, Kindlova D, Izakovic V, Vasku A: Haplotype analysis of the interleukin-18 gene in Czech patients with allergic disorders. Hum Immunol 2010; 71: 592-597.
42. American Academy of Pediatrics: Hepatitis B, in Peter G (ed): Report of the Committee on Infectious Diseases. Red Book, ed 24. Elk Grove Village, American Academy of Pediatrics, 1997.